WO2004022099A3 - Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto - Google Patents

Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto Download PDF

Info

Publication number
WO2004022099A3
WO2004022099A3 PCT/US2003/027588 US0327588W WO2004022099A3 WO 2004022099 A3 WO2004022099 A3 WO 2004022099A3 US 0327588 W US0327588 W US 0327588W WO 2004022099 A3 WO2004022099 A3 WO 2004022099A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
cyclodextrin
methods
covalently bound
therapeutic agents
Prior art date
Application number
PCT/US2003/027588
Other languages
French (fr)
Other versions
WO2004022099A2 (en
Inventor
Jianjun Cheng
Mark E Davis
Kay T Khin
Original Assignee
Insert Therapeutics Inc
Jianjun Cheng
Mark E Davis
Kay T Khin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31982363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004022099(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2003278764A priority Critical patent/AU2003278764C1/en
Priority to JP2004569982A priority patent/JP2006502301A/en
Priority to CA2497792A priority patent/CA2497792C/en
Priority to KR1020137006800A priority patent/KR101476067B1/en
Priority to ES03770286T priority patent/ES2377318T3/en
Priority to AT03770286T priority patent/ATE533513T1/en
Priority to BR122012021252A priority patent/BR122012021252B8/en
Priority to EP03770286A priority patent/EP1534340B1/en
Priority to KR1020167024300A priority patent/KR101857900B1/en
Application filed by Insert Therapeutics Inc, Jianjun Cheng, Mark E Davis, Kay T Khin filed Critical Insert Therapeutics Inc
Priority to MX2013004590A priority patent/MX367615B/en
Priority to KR1020177037716A priority patent/KR102008768B1/en
Priority to BRPI0314042A priority patent/BRPI0314042B8/en
Priority to CN038248298A priority patent/CN1694728B/en
Priority to MXPA05002444A priority patent/MXPA05002444A/en
Priority to KR1020147014132A priority patent/KR20140070676A/en
Publication of WO2004022099A2 publication Critical patent/WO2004022099A2/en
Publication of WO2004022099A3 publication Critical patent/WO2004022099A3/en
Priority to HK05104980.9A priority patent/HK1072202A1/en
Priority to IL234716A priority patent/IL234716A0/en
Priority to IL234715A priority patent/IL234715A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B30/00—Preparation of starch, degraded or non-chemically modified starch, amylose, or amylopectin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44—Polyester-amides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
    • C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
    • C08F220/282—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing two or more oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. In particular, the therapeutic/bioactive agents are covalently bound to the cyclodextrin-containing polymers. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distribution kits containing or relating to the polymeric compounds described herein.
PCT/US2003/027588 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto WO2004022099A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
KR1020147014132A KR20140070676A (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
KR1020177037716A KR102008768B1 (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
MX2013004590A MX367615B (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto.
BRPI0314042A BRPI0314042B8 (en) 2002-09-06 2003-09-04 cyclodextrin-based polymers for the delivery of covalently linked therapeutic agents
JP2004569982A JP2006502301A (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymer for therapeutic agent delivery
AT03770286T ATE533513T1 (en) 2002-09-06 2003-09-04 POLYMERS BASED ON CYCLODEXTRIN FOR ADMINISTRATION OF COVALENTLY BONDED MEDICINAL PRODUCTS
BR122012021252A BR122012021252B8 (en) 2002-09-06 2003-09-04 cyclodextrin-based polymers for the delivery of covalently linked therapeutic agents
EP03770286A EP1534340B1 (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
KR1020167024300A KR101857900B1 (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
AU2003278764A AU2003278764C1 (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for therapeutic delivery
CA2497792A CA2497792C (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for therapeutics delivery
ES03770286T ES2377318T3 (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for the delivery of covalently bound therapeutic agents to them
KR1020137006800A KR101476067B1 (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
CN038248298A CN1694728B (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for therapeutics delivery
MXPA05002444A MXPA05002444A (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto.
HK05104980.9A HK1072202A1 (en) 2002-09-06 2005-06-15 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
IL234716A IL234716A0 (en) 2002-09-06 2014-09-18 Cyclodextrin-based polymers for delivery of therapeutic agents
IL234715A IL234715A0 (en) 2002-09-06 2014-09-18 Cyclodextrin-based polymers for delivery of therapeutic agents

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40885502P 2002-09-06 2002-09-06
US60/408,855 2002-09-06
US42283002P 2002-10-31 2002-10-31
US60/422,830 2002-10-31
US45199803P 2003-03-04 2003-03-04
US60/451,998 2003-03-04

Publications (2)

Publication Number Publication Date
WO2004022099A2 WO2004022099A2 (en) 2004-03-18
WO2004022099A3 true WO2004022099A3 (en) 2004-10-28

Family

ID=31982363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027588 WO2004022099A2 (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto

Country Status (17)

Country Link
US (20) US7270808B2 (en)
EP (4) EP1534340B1 (en)
JP (4) JP2006502301A (en)
KR (6) KR20140070676A (en)
CN (2) CN104383554B (en)
AT (1) ATE533513T1 (en)
AU (2) AU2003278764C1 (en)
BR (2) BRPI0314042B8 (en)
CA (1) CA2497792C (en)
CY (2) CY1112362T1 (en)
ES (3) ES2666694T3 (en)
HK (3) HK1072202A1 (en)
IL (2) IL234716A0 (en)
MX (2) MX367615B (en)
PT (2) PT1534340E (en)
TW (2) TWI422379B (en)
WO (1) WO2004022099A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110179B2 (en) 2002-09-06 2012-02-07 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
DE60323936D1 (en) * 2002-01-14 2008-11-20 Gen Hospital Corp BIOABEAABLE POLYCETALES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE
CA2492803C (en) * 2002-07-19 2013-11-05 The General Hospital Corporation Oxime conjugates and methods for their formation and use
JP4602085B2 (en) * 2002-10-09 2010-12-22 セルリアン・ファーマ・インコーポレイテッド Cyclodextrin-based materials, compositions and related applications
SG129240A1 (en) * 2003-01-23 2007-02-26 Agency Science Tech & Res Biodegradable copolymer and nucleic acid delivery system
JP4009721B2 (en) * 2003-05-23 2007-11-21 独立行政法人産業技術総合研究所 Ion-binding polymer-containing substrate, detection sensor containing the substrate, and pathogen or method for detecting toxins produced by the pathogen
ATE507845T1 (en) * 2003-09-05 2011-05-15 Gen Hospital Corp POLYACETAL DRUG CONJUGATES AS A RELEASE SYSTEM
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
KR20120073370A (en) * 2003-09-17 2012-07-04 넥타르 테라퓨틱스 Multi-arm polymer prodrugs
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
WO2005103068A2 (en) * 2004-04-23 2005-11-03 Novexin Limited Methods and kits for folding proteins in the presence of linear or branched sugar polymers
WO2005120578A2 (en) * 2004-06-07 2005-12-22 California Institute Of Technology Biodegradable drug-polymer delivery system
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006052790A2 (en) 2004-11-05 2006-05-18 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
TW200640493A (en) * 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
CA2608733A1 (en) * 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
EP3088400A1 (en) * 2005-06-22 2016-11-02 Plexxikon Inc. Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors
US20070021380A1 (en) * 2005-07-22 2007-01-25 Leonard Wiebe Novel drug delivery compositions
GT200600381A (en) 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
JP2009509932A (en) * 2005-09-07 2009-03-12 プレキシコン，インコーポレーテッド PPAR active compounds
GT200600407A (en) * 2005-09-07 2007-04-10 ACTIVE PPAR COMPOUNDS
NZ567162A (en) * 2005-09-07 2011-06-30 Plexxikon Inc 1, 3-disubstituted indole derivatives for use as PPAR modulators
CA2633801A1 (en) * 2005-12-19 2007-06-28 Capsutech Ltd. Cyclodextrin-containing polymers and uses thereof
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
RU2008142598A (en) 2006-03-29 2010-05-10 Новартис АГ (CH) SELECTIVE HYDROXAMATE INHIBITORS MMP
US20080027212A1 (en) * 2006-06-28 2008-01-31 Skinner Keith K Methods and compositions for improved uptake of biological molecules
JP5042311B2 (en) 2006-07-20 2012-10-03 ノバルティス アーゲー Aminopiperidine derivatives as CETP inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
JP5277417B2 (en) 2006-11-30 2013-08-28 ネクター セラピューティクス Method for preparing a polymer composite
TW201509433A (en) * 2006-12-13 2015-03-16 Cerulean Pharma Inc Cyclodextrin-based polymers for therapeutics delivery
MX2009006688A (en) 2006-12-21 2009-06-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
PE20121126A1 (en) * 2006-12-21 2012-08-24 Plexxikon Inc PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
RU2009133793A (en) * 2007-02-09 2011-03-20 Энзон Фармасьютикалз, Инк. (Us) TREATMENT OF RESISTANT OR UNRELIABLE CANCER FORMS WITH 7-ETHYL-10-HYDROXYCAMPOTECINE CONJUGATES WITH MULTIPLE CHAIN BRANCHES
PE20090159A1 (en) * 2007-03-08 2009-02-21 Plexxikon Inc INDOL-PROPIONIC ACID DERIVED COMPOUNDS AS PPARs MODULATORS
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP2207570A2 (en) * 2007-09-14 2010-07-21 Nitto Denko Corporation Drug carriers
JP5597396B2 (en) * 2007-09-28 2014-10-01 ナノデックス株式会社 Folic acid-modified cyclodextrin compound, method for producing the same, drug delivery agent for targeted drug delivery system, pharmaceutical composition and contrast agent
CA2702494A1 (en) 2007-10-19 2009-04-23 The Regents Of The University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
KR101564793B1 (en) 2007-11-05 2015-10-30 노파르티스 아게 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
PT2229356E (en) 2007-12-03 2012-01-20 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
EA020114B1 (en) 2008-03-24 2014-08-29 Новартис Аг Arylsulfonamide-based matrix metalloprotease inhibitors
AU2009231804B2 (en) 2008-03-31 2015-06-04 Boston Medical Center Corporation Predictive marker for topoisomerase I inhibitors
BRPI0911332A2 (en) 2008-04-04 2019-09-24 Calando Pharmaceuticals Inc compositions and use of epas1 inhibitors
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (en) * 2008-05-19 2009-12-16 Plexxikon Inc PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS
WO2009152087A1 (en) * 2008-06-10 2009-12-17 Plexxikon, Inc. Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
EP2313411A1 (en) * 2008-06-10 2011-04-27 Plexxikon, Inc. 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor
CA2732508C (en) 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
WO2010019718A2 (en) 2008-08-13 2010-02-18 California Institute Of Technology Carrier nanoparticles and related compositions, methods and systems
WO2010025337A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068283A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex VIVO modifiable particle or polymeric material medicament carrier
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
ES2744975T3 (en) 2008-09-23 2020-02-27 Nektar Therapeutics Metronome dosage method with camptothecin prodrugs (eg PEG-Irinotecan)
AU2009307922A1 (en) * 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
JP5593488B2 (en) * 2008-11-17 2014-09-24 独立行政法人国立がん研究センター A novel cancer targeting treatment with a complex of a substance capable of binding specifically to a constituent of cancer stroma and an antitumor compound
CL2009002167A1 (en) * 2008-12-10 2010-10-15 Mersana Therapeutics Inc Pharmaceutical formulation for intravenous administration comprising a compound derived from biocompatible and biodegradable camptothecin-polymer conjugates, a stabilizing agent, one or more buffers and a surfactant, useful for the treatment of cancer.
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
US9845237B2 (en) 2009-02-26 2017-12-19 The Regents Of The University Of California Supramolecular approach for preparation of size controllable nanoparticles
AR076105A1 (en) * 2009-03-11 2011-05-18 Plexxikon Inc PIRROL DERIVATIVES [2,3-B] PIRIDINE TO INHIBIT THE RAF QUINASA
MY161861A (en) 2009-03-11 2017-05-15 Plexxikon Inc Pyrrolo [2,3-] pyridine kinase inhibitors
EA031116B1 (en) * 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг PROPANE-1-SULFONIC ACID {3-[5-(4-CHLORO-PHENYL)-1H-PYRROLO[2,3-b]PYRIDINE-3-CARBONYL]-2,4-DIFLUORO-PHENYL}AMIDE CRYSTALLINE POLYMORPH FORMS
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2010138802A2 (en) 2009-05-28 2010-12-02 Cornell University Compositions and their use for removing cholesterol
JP5747432B2 (en) * 2009-05-28 2015-07-15 国立大学法人秋田大学 Disubstituted cyclodextrin and method for detecting nucleic acid using the same
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US20110152512A1 (en) * 2009-09-09 2011-06-23 John Ryan Cyclodextrin-based polymers for therapeutics delivery
AU2010295646B2 (en) * 2009-09-15 2016-02-11 Ellipses Pharma Limited Treatment of cancer
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
US8460745B2 (en) * 2009-09-20 2013-06-11 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
MX2012005284A (en) * 2009-11-06 2012-06-28 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
CN105906631A (en) 2009-11-18 2016-08-31 普莱希科公司 Compounds and methods for kinase modulation, and indications therefor
AU2010321533A1 (en) * 2009-11-23 2012-05-31 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
AU2010336524B2 (en) 2009-12-23 2015-10-08 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20120004195A1 (en) * 2010-01-19 2012-01-05 Alexandra Glucksmann Cyclodextrin-based polymers for therapeutic delivery
JP2011190341A (en) * 2010-03-15 2011-09-29 Nano Dex Kk Cyclodextrin compound
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treatment of autoimmune and other diseases
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US20120213854A1 (en) * 2010-09-30 2012-08-23 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
CA2813466A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012092339A2 (en) * 2010-12-28 2012-07-05 The Children's Hospital Of Philadelphia The design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations
WO2012103182A1 (en) 2011-01-28 2012-08-02 Cerulean Pharma Inc. Method for fabricating nanoparticles
PT2672967T (en) 2011-02-07 2018-12-07 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
WO2012145632A1 (en) * 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN110511939A (en) 2011-10-03 2019-11-29 现代泰克斯公司 Nucleosides, nucleotide and nucleic acid of modification and application thereof
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
WO2013116200A1 (en) * 2012-01-31 2013-08-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20150051269A1 (en) * 2012-03-13 2015-02-19 Postech Academy-Industry Foundation Drug Delivery Conjugate Capable of Controlled Release, and Use Thereof
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013158710A2 (en) 2012-04-18 2013-10-24 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
AU2013262320B2 (en) 2012-05-16 2018-02-22 Techfields Pharma Co., Ltd. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
AU2013312477B2 (en) 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EA201590622A1 (en) 2012-10-16 2015-10-30 Эндосайт, Инк. CONJUGATES FOR DELIVERY OF MEDICINES CONTAINING NOT MEETING IN THE NATURE OF AMINO ACID AND METHODS OF APPLICATION
US11467158B2 (en) 2012-10-29 2022-10-11 Boston Medical Center Corporation BRCA1 mutations as predictive markers for topoisomerase inhibitions
PT2922554T (en) 2012-11-26 2022-06-28 Modernatx Inc Terminally modified rna
WO2014093343A2 (en) * 2012-12-10 2014-06-19 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
CN103044349B (en) * 2012-12-13 2014-05-21 浙江大学 Microwave-assisted method for preparing ethylenediamine tetraacetic dianhydride by using nano-ferrite
CA2895239C (en) 2012-12-21 2020-10-27 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014130994A1 (en) * 2013-02-25 2014-08-28 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents
US9132097B2 (en) 2013-03-01 2015-09-15 California Institute Of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP2972349B1 (en) 2013-03-14 2019-10-23 University Of Washington Through Its Center For Commercialization Polymer dot compositions and related methods
RS57733B1 (en) 2013-03-15 2018-12-31 Plexxikon Inc Heterocyclic compounds and uses thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014274093B2 (en) 2013-05-30 2018-11-08 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
JP2016530294A (en) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Chimeric polynucleotide
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
EP3062742B1 (en) 2013-11-01 2021-12-01 Lensgen, Inc. Two-part accommodating intraocular lens device
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2015179402A1 (en) * 2014-05-19 2015-11-26 North Carolina State University Methods of folding a graft copolymer with dual anticancer drugs and related applications
JP6602834B2 (en) 2014-06-30 2019-11-06 ターベダ セラピューティクス インコーポレイテッド Targeted conjugates and particles and formulations thereof
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
US10004596B2 (en) 2014-07-31 2018-06-26 Lensgen, Inc. Accommodating intraocular lens device
AU2015318233B2 (en) 2014-09-15 2020-03-12 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN104274837B (en) * 2014-09-18 2017-01-11 福格森（武汉）生物科技股份有限公司 Nilotinib oral preparation
CN104311820B (en) * 2014-09-24 2017-06-20 北京化工大学 A kind of method that degradable medicaments carrier is built based on polysaccharide graft poly-aspartate benzyl ester
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI547308B (en) * 2015-06-10 2016-09-01 聚和國際股份有限公司 Method for preparation of polyelectrolyte capsule and polyelectrolyte capsule prepared by the same
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems
WO2017006279A1 (en) * 2015-07-08 2017-01-12 Aten Porus Lifesciences Cyclodextrin-polymer complexes and compostions and methods of making and using the same
PL3324932T3 (en) * 2015-07-22 2021-07-05 Nitto Denko Corporation Compositions and methods for nanoparticle lyophile forms
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017024182A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
WO2017053243A1 (en) 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof
JP7057278B2 (en) 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド SSTR targeted conjugates and particles and their formulations
WO2017096087A1 (en) 2015-12-01 2017-06-08 Daniel Brady Accommodating intraocular lens device
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
MX2018008888A (en) * 2016-01-21 2019-06-13 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof.
WO2017176807A2 (en) 2016-04-04 2017-10-12 University Of Virginia Patent Foundation Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2018053201A1 (en) 2016-09-14 2018-03-22 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
TW201815766A (en) 2016-09-22 2018-05-01 美商普雷辛肯公司 Compounds and methods for IDO and TDO modulation, and indications therefor
KR20190064600A (en) 2016-09-23 2019-06-10 듀크 유니버시티 Unstructured non-repetitive polypeptides with LCST behavior
AU2017359043B2 (en) 2016-11-08 2022-06-16 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
WO2018136202A2 (en) 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
EP3565848A4 (en) 2017-01-03 2020-09-02 The University of North Carolina at Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CN110461338A (en) 2017-03-28 2019-11-15 北卡罗来纳大学查佩尔希尔分校 The nitric oxide production poly- aminoglycoside of release and preparation method as biodegradable antibacterial bracket
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2018213077A1 (en) * 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
CA3068318A1 (en) 2017-06-30 2019-01-03 Massachusetts Institute Of Technology Branched multi-functional macromonomers and related polymers and uses thereof
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
EP3706735A1 (en) 2017-11-06 2020-09-16 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
WO2019173539A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
JP2021518367A (en) 2018-03-20 2021-08-02 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Compounds and methods for IDO and TDO regulation, and signs for them
US20210128734A1 (en) * 2018-04-30 2021-05-06 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US10988491B2 (en) 2018-08-17 2021-04-27 Massachusetts Institute Of Technology Degradable polymers of a cyclic silyl ether and uses thereof
JP2022516461A (en) 2018-12-28 2022-02-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Nitric oxide-releasing antibacterial polymer and scaffolds made from it, and methods associated with it.
US20220133692A1 (en) * 2019-01-31 2022-05-05 Northwestern University Supramolecular photoprotection of a photosensitizer
CN113710668A (en) 2019-04-09 2021-11-26 普莱希科公司 Condensed azines for EP300 or CBP modulation and indications therefor
KR20220010525A (en) 2019-05-20 2022-01-25 메사추세츠 인스티튜트 오브 테크놀로지 Boronic acid ester prodrugs and uses thereof
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021113625A1 (en) 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
KR20210071296A (en) * 2019-12-06 2021-06-16 (주) 에이치엔에이파마켐 Composite for transdermal transfer using covalent organic framework and polymer
WO2021141662A1 (en) 2020-01-10 2021-07-15 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof
CN111443068B (en) * 2020-03-06 2023-06-27 天津大学 Pure organic room temperature phosphorescent material with multiple stimulus response characteristics, screening method and application
WO2021202900A1 (en) 2020-04-02 2021-10-07 Plexxikon Inc. 1,6-naphthyridine compounds and methods for csk modulation and indications therefor
JP2023522949A (en) 2020-04-23 2023-06-01 オプナ バイオ ソシエテ アノニム Compounds and methods for modulating CD73 and indications thereof
CA3187357A1 (en) * 2020-06-15 2021-12-23 Nanosynthons Llc Excipients providing stabilization and enhanced water solubilization and their uses
EP4192509A1 (en) 2020-08-05 2023-06-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022061251A1 (en) 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN112755197B (en) * 2020-10-09 2023-01-13 黑龙江大学 Cyclodextrin drug inclusion compound and preparation method and application thereof
WO2022159319A2 (en) * 2021-01-19 2022-07-28 Mountain Valley Md Inc A porous aluminum nanoparticulate structure
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
CN115160454A (en) * 2021-04-01 2022-10-11 四川大学 Supermolecule polyaldehyde compound based on poly-beta-cyclodextrin and adamantane host-guest action and preparation method thereof
CN113274541A (en) * 2021-05-10 2021-08-20 四川大学 Antibacterial collagen-based medical material and preparation method thereof
KR20230050084A (en) * 2021-10-07 2023-04-14 주식회사 셀진 Drug delivery system comprising polylactic-co-glycolic acid and beta-cyclodextrin containing drug
WO2023113479A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
CN114470237B (en) * 2022-03-21 2023-12-19 中国科学院长春应用化学研究所 Virus-like structural gene vector, drug delivery system, preparation method and application thereof
CN115006549A (en) * 2022-06-16 2022-09-06 湖南科技大学 Preparation method of acid-sensitive cross-linked cyclodextrin nano-hydrogel drug delivery system with controllable particle size and controllable degradation
CN115340615B (en) * 2022-08-12 2023-05-02 同济大学 Fluorescent molecule based on cyclodextrin-amino acid and synthetic method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013100A1 (en) * 1990-03-02 1991-09-05 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
EP0730869A1 (en) * 1994-09-24 1996-09-11 Nobuhiko Yui Biodegradable medicinal polymer assembly with supermolecular structure
WO1998047496A2 (en) * 1997-04-18 1998-10-29 Access Pharmaceuticals, Inc. Polymer-platinum compounds
WO2000001734A1 (en) * 1998-07-01 2000-01-13 California Institute Of Technology Linear cyclodextrin copolymers

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2131201A (en) 1928-08-04 1938-09-27 Gen Motors Corp Composite clutch
US2129408A (en) 1936-07-02 1938-09-06 Arthur C Davidson Truck stabilizer
US2129401A (en) 1937-09-09 1938-09-06 Botinger Fred Flexible utility ladder
US2131208A (en) 1938-02-26 1938-09-27 Union Switch & Signal Co Remote indication apparatus
US3472835A (en) * 1964-02-12 1969-10-14 American Mach & Foundry Schardinger dextrins
US3454530A (en) * 1966-03-07 1969-07-08 Leslie C Case Novel polyols which are reaction products of a monoepoxide and a cyclic monoanhydride
US3453257A (en) * 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3654261A (en) * 1968-06-27 1972-04-04 Cpc International Inc Quaternary ammonium alkoxide alkoxy polyol compounds
USRE32268E (en) * 1973-03-01 1986-10-21 Strategic Medical Research Corp. Therapeutic composition and method of therapeutically treating warm blooded animals therewith
GB1390479A (en) 1973-09-05 1975-04-16 I Orch Sinteza Akademii Nauk L Pharmaceutical composition for treatment of parkinsonism
DE2843963A1 (en) 1978-10-09 1980-04-24 Merck Patent Gmbh BODY-RESORBABLE SHAPED MATERIAL BASED ON COLLAGEN AND THEIR USE IN MEDICINE
DE2842862A1 (en) * 1978-10-02 1980-04-10 Boehringer Mannheim Gmbh METHOD FOR DETERMINING ION, POLAR AND / OR LIPOPHILE SUBSTANCES IN LIQUIDS
CA1190855A (en) 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
JPS58113198A (en) * 1981-12-26 1983-07-05 Hidetoshi Tsuchida Porphyrin compound bonded with cyclodextrin
US4570629A (en) 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
JPS58167613A (en) 1982-03-26 1983-10-03 Mitsubishi Petrochem Co Ltd Preparation of water-soluble cyclodextrin-containing polymer
ATE37983T1 (en) 1982-04-22 1988-11-15 Ici Plc DELAYED RELEASE AGENT.
CA1208558A (en) 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
EP0130935B1 (en) 1983-07-01 1987-04-15 Battelle Memorial Institute Biodegradable polypeptide and its use in the sustained release of medicaments
US4525495A (en) 1983-07-22 1985-06-25 The Dow Chemical Company Mineral filled composites
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8416234D0 (en) 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
CH663951A5 (en) 1984-10-10 1988-01-29 Nestle Sa PROCESS FOR THE SELECTIVE ENRICHMENT OF POLYUNSATURATED FATTY ACIDS IN A MIXTURE CONTAINING ENRICHED FRACTION FATTY ACIDS AND COMPOSITIONS CONTAINING THE SAME.
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
JPH0651725B2 (en) * 1985-02-28 1994-07-06 メルシャン株式会社 Partially methylated cyclodextrin and method for producing the same
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4841081A (en) * 1985-10-16 1989-06-20 Osaka Soda Co., Ltd. Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound
FR2601675B1 (en) 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0258780B1 (en) 1986-09-05 1993-06-23 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
GB2197720A (en) 1986-11-20 1988-05-25 Nat Res Dev Immobilisation of polynucleotides
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
WO1988010297A1 (en) * 1987-06-17 1988-12-29 Princess Margaret Children's Medical Research Foun Cloning of mite allergens
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
US4941996A (en) 1987-10-19 1990-07-17 Minnesota Mining And Manufacturing Company Inclusion complexes providing second harmonic generation
US5760015A (en) 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
JP2670680B2 (en) 1988-02-24 1997-10-29 株式会社ビーエムジー Polylactic acid microspheres containing physiologically active substance and method for producing the same
JP2614081B2 (en) 1988-05-27 1997-05-28 大塚化学株式会社 Method for producing optically active β-lactam derivative
US4887778A (en) 1988-06-01 1989-12-19 Universal Instruments Corporation Feeder drive assembly and replaceable section for tape supplying and cover peeling
JPH01319502A (en) * 1988-06-21 1989-12-25 Showa Denko Kk Cyclodextrin derivative and production thereof
HU200913B (en) 1988-07-28 1990-09-28 Ciklodextrin Kutato Fejlesztoe Process for producing infusion stock-solution containing pharmaceutically active components of bad water solubility
MY106598A (en) 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US4902788A (en) 1988-09-29 1990-02-20 Uop Crosslinked cyclodextrins supported on porous refractory inorganic oxides
US5098793A (en) * 1988-09-29 1992-03-24 Uop Cyclodextrin films on solid substrates
IT1230566B (en) 1988-10-17 1991-10-28 Vectorpharma Int LITTLE SOLUBLE DRUGS SUPPORTED ON POLYMERIC SUBSTANCES IN A FORM THAT WILL INCREASE THE DISSOLUTION SPEED
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH03221505A (en) 1990-01-29 1991-09-30 Toppan Printing Co Ltd Synthesis of cyclodextrin polymer and production of cyclodextrin film
IT1241417B (en) * 1990-03-06 1994-01-14 Vectorpharma Int THERAPEUTIC COMPOSITIONS WITH CONTROLLED RELEASE OF DRUGS SUPPORTED ON CROSS-LINKED POLYMERS AND COATED WITH POLYMER FILM, AND THEIR PREPARATION PROCESS
DE4009825A1 (en) * 1990-03-27 1991-10-02 Consortium Elektrochem Ind WATER-INSOLUBLE CYCLODEXTRIN POLYMERISATES AND METHOD FOR PRODUCING THE SAME
US5139687A (en) 1990-05-09 1992-08-18 The Proctor & Gamble Company Non-destructive carriers for cyclodextrin complexes
JPH0425505A (en) 1990-05-21 1992-01-29 Toppan Printing Co Ltd Cyclodextrain polymer and production of cyclodextrin membrane
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
FR2665169A1 (en) 1990-07-30 1992-01-31 Rhone Poulenc Chimie Cyclodextrin inclusion compounds containing phenolic antioxidants and their use in polymers
JPH04106101A (en) 1990-08-27 1992-04-08 Showa Denko Kk Cyclodextrin polymer and its production
DE69103503T2 (en) * 1990-09-28 1995-01-05 Mercian Corp Adriamycin derivatives.
JPH059205A (en) * 1990-09-28 1993-01-19 Mercian Corp New adriamycin derivative
KR920702376A (en) 1990-10-01 1992-09-03 후지다 히로미찌 Cyclodextrin polymer and cyclodextrin membrane using the polymer
KR927003647A (en) * 1990-11-30 1992-12-18 돕빵 인사쯔 가부시끼가이샤 Method for preparing cyclodextrin derivatives and cyclodextrin immobilized polymer
ATE244065T1 (en) 1990-12-06 2003-07-15 Affymetrix Inc METHODS AND REAGENTS FOR VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS
US5148854A (en) * 1990-12-11 1992-09-22 Toshiba Kikai Kabushiki Kaisha Counting die cast manufactured goods
NO180605C (en) * 1990-12-19 2003-08-28 Geco As Device for weight load of streamer cable
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
EP0602149A1 (en) 1991-09-06 1994-06-22 Commonwealth Scientific And Industrial Research Organisation Composition and method for reducing cholesterol concentration
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
JPH07503943A (en) 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド Cross-linked polysaccharides, polycations and lipids useful for encapsulation and drug release
US6864101B1 (en) * 1991-11-22 2005-03-08 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
JP2976154B2 (en) 1991-11-27 1999-11-10 コニカ株式会社 Solid processing agents for silver halide photographic materials
JP3221505B2 (en) 1992-02-06 2001-10-22 日本信号株式会社 Mobile operation control device
US5219980A (en) 1992-04-16 1993-06-15 Sri International Polymers biodegradable or bioerodiable into amino acids
JPH05331074A (en) 1992-05-27 1993-12-14 Nippon Oil & Fats Co Ltd Drug carrier
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
IT1256134B (en) 1992-09-09 1995-11-29 Luigi Boltri LYPHOPHILIC SALTS CONTAINING ACTUABLE NEUTRON ISOTOPES AND COMPOSITIONS CONTAINING THEM
US5482719A (en) * 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
EP0624166B1 (en) * 1992-11-30 1997-04-16 Novartis AG Polymerizable carbohydrate esters, polymers made from such esters and the use of such polymers
FR2698543B1 (en) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa New taxoid-based compositions.
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
BR9405798A (en) 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Methods for in vivo release of biological material and useful compositions thereof
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
US5840485A (en) * 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
TW328535B (en) * 1993-07-02 1998-03-21 Novartis Ag Functional photoinitiators and their manufacture
JP3288149B2 (en) 1993-08-05 2002-06-04 日本食品化工株式会社 Cyclodextrin polymer and method for producing the same
RU2094059C1 (en) 1993-08-30 1997-10-27 Московский государственный университет, химический факультет Method of transport of neurotropic preparation to brain
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US5880154A (en) * 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
TW307775B (en) 1994-02-15 1997-06-11 Novartis Erfind Verwalt Gmbh Unsaturated carbohydrate derivatives, polymers thereof and their use
MX9504664A (en) 1994-03-07 1997-05-31 Dow Chemical Co Bioactive and/or targeted dendrimer conjugates.
JPH07316205A (en) 1994-03-30 1995-12-05 D D S Kenkyusho:Kk Cyclodextrin derivative
HU218280B (en) 1994-04-26 2000-07-28 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
US6589736B1 (en) * 1994-11-22 2003-07-08 The Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5691316A (en) 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5716594A (en) * 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
US5679773A (en) * 1995-01-17 1997-10-21 Affymax Technologies N.V Reagants and methods for immobilized polymer synthesis and display
DE69531545T2 (en) * 1994-06-23 2004-06-24 Affymax Technologies N.V., Willemstad PHOTOLABILE CONNECTIONS AND METHOD FOR THE USE THEREOF
US5776842A (en) 1994-06-23 1998-07-07 Cellresin Technologies, Llc Cellulosic web with a contaminant barrier or trap
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5494854A (en) 1994-08-17 1996-02-27 Texas Instruments Incorporated Enhancement in throughput and planarity during CMP using a dielectric stack containing HDP-SiO2 films
US5548932A (en) * 1994-11-08 1996-08-27 Maxcess Technologies, Inc. Adjustable cable tray support system
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
MA23823A1 (en) 1995-03-27 1996-10-01 Aventis Pharma Sa NEW TAXOIDS, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
US5728804A (en) * 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
US6667293B1 (en) 1995-09-12 2003-12-23 Hybridon, Inc. Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
JP3830198B2 (en) 1996-03-29 2006-10-04 東光薬品工業株式会社 Skin-permeable indomethacin external preparation using supramolecular structure polymer aggregate
DE19612768A1 (en) 1996-03-29 1997-10-02 Basf Ag Polymers containing cyclodextrin groups, process for their preparation and their use
JPH11514388A (en) * 1996-04-03 1999-12-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Cyclodextrin compounds and their production and use
DE19629494A1 (en) 1996-07-09 1998-01-15 Schering Ag Pseudopolyrotaxanes
US5844030A (en) * 1996-07-09 1998-12-01 Andros; Nicholas Charged ion cleaning devices and cleaning system
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
EP0946286B1 (en) 1996-11-14 2003-03-19 Affymetrix, Inc. Chemical amplification for the synthesis of patterned arrays
JPH10158195A (en) 1996-11-28 1998-06-16 Res Inst For Prod Dev Production of drug-polymer composite reparation using coordination bond
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
HUP9700632A3 (en) 1997-03-24 1999-10-28 Cyclolab Ciklodextrin Kutato F Pharmaceutical compositions containing propylamine derivative and cyclodextrine and process for producing the same
EP1003555A1 (en) 1997-04-23 2000-05-31 The University of Otago Controlled release of ophthalmic compositions
EP0979311A1 (en) 1997-04-30 2000-02-16 Of The University Of Minnesota Regents $i(IN VIVO) USE OF RECOMBINAGENIC OLIGONUCLEOBASES TO CORRECT GENETIC LESIONS IN HEPATOCYTES
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
JP2002506436A (en) * 1997-06-13 2002-02-26 ザ ジョンズ ホプキンス ユニバーシティー Therapeutic nanospheres
DE19726186A1 (en) 1997-06-20 1998-12-24 Boehringer Ingelheim Int Complexes for the transport of nucleic acid into higher eukaryotic cells
JPH11100401A (en) * 1997-07-30 1999-04-13 Kikkoman Corp Cyclic oligosaccharide and preventive or treating agent for retrovirus disease containing the same
US6410342B1 (en) * 1997-08-19 2002-06-25 Pharmacopeia, Inc. Method and apparatus for controlled photoelution
ATE347911T1 (en) * 1997-09-15 2007-01-15 Genetic Immunity Llc COMPOSITIONS FOR DELIVERY OF GENES TO ANTIGEN-PRESENTING CELLS OF THE SKIN
CA2312975C (en) 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
GB9801109D0 (en) 1998-01-20 1998-03-18 Pfizer Cyclodextrin compositions
EP2332645A1 (en) * 1998-02-11 2011-06-15 The University Of Houston Apparatus for chemical and biochemical reactions using photo-generated reagents
IT1298732B1 (en) 1998-03-13 2000-02-02 Recordati Chem Pharm ORAL PHARMACEUTICAL COMPOSITIONS ASSUMABLE WITHOUT LIQUIDS, CONTAINING INCLUSION COMPLEXES
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
WO1999061062A1 (en) 1998-05-29 1999-12-02 Massachusetts Institute Of Technology Cyclodextrin complexes
US7091192B1 (en) * 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
AU756796B2 (en) 1998-10-16 2003-01-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Combination therapy with VIP antagonist
ATE356637T1 (en) 1998-12-04 2007-04-15 California Inst Of Techn DRUGS CONTAINING SUPRAMOLECULAR COMPLEXES
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
BR9916518A (en) 1998-12-23 2002-01-29 Searle & Co A method for treating or preventing a neoplasm disorder in a mammal in need of such treatment or prevention, and a combination comprising a cyclooxygenase-2 inhibitor and one or more antineoplastic agents.
US6740643B2 (en) * 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
FR2789685B1 (en) * 1999-02-15 2001-05-04 Univ Lille Sciences Tech PROCESS FOR MANUFACTURING SOLUBLE AND INSOLUBLE POLYMERS BASED ON CYCLODEXTRIN (S) AND / OR DERIVATIVES OF CYCLODEXTRIN (S) AND SOLUBLE POLYMERS BASED ON CYCLODEXTRIN (S) AND / OR DERIVATIVES OF CYCLODEXTRIN (S)
AUPP913999A0 (en) * 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
FR2792942B1 (en) 1999-04-29 2001-06-08 Commissariat Energie Atomique AMPHIPHILIC CYCLODEXTRINS, THEIR PREPARATION AND THEIR USE FOR SOLUBILIZING ORGANIZED SYSTEMS AND INCORPORATING HYDROPHOBIC MOLECULES
JP2003501440A (en) 1999-06-07 2003-01-14 マイラス コーポレーション Compound containing reactive disulfide bond
DK1102785T3 (en) 1999-06-07 2013-05-13 Arrowhead Res Corp Compositions for drug delivery using pH-sensitive molecules
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6420378B1 (en) 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
EP1233671A4 (en) 1999-11-29 2005-11-02 Mirus Corp Compositions and methods for drug delivery using amphiphile binding molecules
SK282717B6 (en) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Preparation method of ultrahigh molecular hyaluronans
US20010041706A1 (en) 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism
AU2001240024A1 (en) * 2000-03-31 2001-10-15 Supergen, Inc. Camptothecin complexes
JP2001288097A (en) 2000-04-07 2001-10-16 Pg-Txl Co Lp Water-soluble paclitaxel derivative
JP2004501143A (en) 2000-06-22 2004-01-15 ニトロメド　インコーポレーテッド Nitrosated and nitrosylated taxanes, compositions and methods of use
US6664228B1 (en) 2000-08-10 2003-12-16 Ceramoptec Industries, Inc. Photoselective marking of biological targets
CA2417087A1 (en) 2000-08-01 2002-02-07 Oregon Health And Science University Mammalian dna binding membrane-associated protein-encoding gene and uses
TWI321054B (en) * 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
CA2435287A1 (en) 2001-01-17 2002-07-25 Zycos Inc. Nucleic acid delivery formulations
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6828392B2 (en) 2001-08-28 2004-12-07 Carlsberg A/S Hydroxy and amine functionalized resins
US20030129262A1 (en) 2001-08-30 2003-07-10 Epner Daniel E. Methionine restriction for cancer therapy
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
US20030134824A1 (en) 2001-11-12 2003-07-17 Ronald Breslow Beta-cyclodextrin dimers and phthalocyanines and uses thereof
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
US6527887B1 (en) * 2002-01-18 2003-03-04 Mach I, Inc. Polymeric cyclodextrin nitrate esters
CN1305932C (en) * 2002-02-22 2007-03-21 植入疗法公司 Carbohydrate-modified polymers, compositions and uses related thereto
KR20040088519A (en) * 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. Active Agent Delivery Systems and Methods for Protecting and Administering Active Agents
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
ES2601143T3 (en) 2002-07-19 2017-02-14 Omeros Corporation Biodegradable triblock copolymers, synthesis methods thereof, and hydrogels and biomaterials prepared therefrom.
AU2003265576A1 (en) 2002-08-23 2004-03-11 The Mclean Hospital Corporation Corticosteroid conjugates and uses thereof
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
CN1694728B (en) 2002-09-06 2011-12-28 天蓝制药公司 Cyclodextrin-based polymers for therapeutics delivery
US20040047835A1 (en) 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
CA2497792C (en) 2002-09-06 2014-08-05 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2004032866A2 (en) 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Therapeutic formulations
JP4602085B2 (en) * 2002-10-09 2010-12-22 セルリアン・ファーマ・インコーポレイテッド Cyclodextrin-based materials, compositions and related applications
CN1309763C (en) 2002-10-31 2007-04-11 日本化药株式会社 High-molecular weight derivatives of camptothecins
JP2006507841A (en) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
CN1216057C (en) 2003-03-28 2005-08-24 贵州省生物研究所 Derivative of camptothecin kind analogue and its preparation method
RS20181002A1 (en) 2003-05-30 2018-12-31 Genentech Inc Treatment with anti-vegf antibodies
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
CA2547934C (en) 2004-02-19 2013-05-21 Abbott Laboratories Methods of using gamma cyclodextrin to control blood glucose and insulin secretion
JP2008504809A (en) 2004-06-04 2008-02-21 ジェネンテック・インコーポレーテッド EGFR mutation
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
AU2005316652B2 (en) 2004-12-15 2009-07-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinations of therapeutic agents for treating cancer
TW200640493A (en) 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
EA015987B1 (en) 2005-02-24 2012-01-30 Элан Фарма Интернэшнл Лимитед Composition for injections comprising nanoparticulate formulations of docetaxel and surface stabilizer
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
DK1913157T4 (en) 2005-06-28 2017-01-23 Genentech Inc EGFR and KRAS mutations for predicting patient response to EGFR inhibitor therapy.
JP4994618B2 (en) 2005-08-11 2012-08-08 学校法人北里研究所 Chemoradiation with TS-1 / camptothecins
US8143236B2 (en) 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
EP1996612A4 (en) 2006-03-03 2010-10-20 Univ Kingston Compositions for treatment of cancer
KR100917809B1 (en) 2006-05-22 2009-09-18 에스케이케미칼주식회사 Stable Pharmaceutical Composition containing Docetaxel
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
TW201509433A (en) 2006-12-13 2015-03-16 Cerulean Pharma Inc Cyclodextrin-based polymers for therapeutics delivery
US20080176958A1 (en) * 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20110177161A1 (en) 2007-05-24 2011-07-21 Dr. Reddy's Laboratories Limited Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin
FR2918279B1 (en) 2007-07-05 2010-10-22 Aventis Pharma Sa ANTITUMOR COMBINATIONS CONTAINING A VEGF INHIBITOR AGENT AND IRINOTECAN
US20100273859A1 (en) 2007-12-14 2010-10-28 The Brigham And Women's Hospital, Inc. Treatment and prevention of hiv infection
BRPI0911332A2 (en) 2008-04-04 2019-09-24 Calando Pharmaceuticals Inc compositions and use of epas1 inhibitors
WO2010025337A1 (en) 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
WO2010043050A1 (en) 2008-10-16 2010-04-22 Celator Pharmaceuticals Corporation Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
WO2010117668A1 (en) 2009-03-30 2010-10-14 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
AU2010295646B2 (en) 2009-09-15 2016-02-11 Ellipses Pharma Limited Treatment of cancer
US20120114658A1 (en) 2009-09-15 2012-05-10 John Ryan Treatment of cancer
US20110245201A1 (en) 2009-09-15 2011-10-06 John Ryan Treatment of cancer
US20130029909A1 (en) 2009-09-15 2013-01-31 John Ryan Treatment of cancer
AU2010321533A1 (en) 2009-11-23 2012-05-31 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treatment of autoimmune and other diseases
US20120213854A1 (en) 2010-09-30 2012-08-23 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2013037789A1 (en) 2011-09-12 2013-03-21 Universiteit Gent Neuregulin-1-based prognosis and therapeutic stratification of colorectal cancer
WO2013059651A1 (en) 2011-10-21 2013-04-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bifunctional compounds
US20140105891A1 (en) 2012-10-05 2014-04-17 Cerulean Pharma Inc. Treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013100A1 (en) * 1990-03-02 1991-09-05 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
EP0730869A1 (en) * 1994-09-24 1996-09-11 Nobuhiko Yui Biodegradable medicinal polymer assembly with supermolecular structure
WO1998047496A2 (en) * 1997-04-18 1998-10-29 Access Pharmaceuticals, Inc. Polymer-platinum compounds
WO2000001734A1 (en) * 1998-07-01 2000-01-13 California Institute Of Technology Linear cyclodextrin copolymers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HRISTOVA-KAZMIERSKI M K ET AL: "A new approach to enhance bioavailability of biologically active peptides: Conjugation of a [delta]-opioid agonist to [beta]-cyclodextrin", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 1993 UNITED KINGDOM, vol. 3, no. 5, 1993, pages 831 - 834, XP002270032, ISSN: 0960-894X *
HUH, K.M.; TOMITA, H.; LEE, W.K.; OOYA, T.; YUI, N.: "Synthesis of alpha-Cyclodextrin-Conjugated Poly(epsilon-Lysine)s and Their Inclusion Complexation Behavior", MACROMOLECULAR RAPID COMMUNICATIONS, WILEY-VCH VERLAG GMBH, vol. 23, no. 3, February 2002 (2002-02-01), WEINHEIM, GERMANY, pages 179 - 182, XP002270033 *
ORTEGA-CABALLERO F ET AL: "Binding affinity properties of dendritic glycosides based on a [beta]-cyclodextrin core toward guest molecules and concanavalin A", JOURNAL OF ORGANIC CHEMISTRY 16 NOV 2001 UNITED STATES, vol. 66, no. 23, 16 November 2001 (2001-11-16), pages 7786 - 7795, XP002270034, ISSN: 0022-3263 *
YANO H ET AL: "Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 79, no. 1-3, 19 February 2002 (2002-02-19), pages 103 - 112, XP004340916, ISSN: 0168-3659 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110179B2 (en) 2002-09-06 2012-02-07 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof

Also Published As

Publication number Publication date
AU2003278764C1 (en) 2010-09-16
US8389499B2 (en) 2013-03-05
US8399431B2 (en) 2013-03-19
US20140044669A1 (en) 2014-02-13
US8518388B2 (en) 2013-08-27
AU2009251190C1 (en) 2013-03-14
CN104383554A (en) 2015-03-04
US20040077595A1 (en) 2004-04-22
KR20160106223A (en) 2016-09-09
ES2666694T3 (en) 2018-05-07
IL234716A0 (en) 2014-11-30
WO2004022099A2 (en) 2004-03-18
KR20130033467A (en) 2013-04-03
MXPA05002444A (en) 2005-09-30
US9550860B2 (en) 2017-01-24
EP1534340A2 (en) 2005-06-01
US20120065368A1 (en) 2012-03-15
US20130165405A1 (en) 2013-06-27
US8252276B2 (en) 2012-08-28
US20210128516A1 (en) 2021-05-06
JP5586487B2 (en) 2014-09-10
KR101476067B1 (en) 2014-12-23
US8580243B2 (en) 2013-11-12
ATE533513T1 (en) 2011-12-15
US20150165055A1 (en) 2015-06-18
KR20140070676A (en) 2014-06-10
CN104383554B (en) 2018-06-08
US8314230B2 (en) 2012-11-20
US20080058427A1 (en) 2008-03-06
BR122012021252B1 (en) 2018-07-10
JP5934743B2 (en) 2016-06-15
HK1072202A1 (en) 2005-08-19
US20170369651A1 (en) 2017-12-28
KR102008768B1 (en) 2019-08-08
CY1114941T1 (en) 2016-12-14
IL234715A0 (en) 2014-11-30
US20130039880A1 (en) 2013-02-14
AU2003278764B2 (en) 2010-02-04
CN102516417A (en) 2012-06-27
AU2009251190A1 (en) 2010-01-21
AU2003278764A1 (en) 2004-03-29
US20130203700A1 (en) 2013-08-08
US20130129665A1 (en) 2013-05-23
HK1151467A1 (en) 2012-02-03
TW200423947A (en) 2004-11-16
US20130156721A1 (en) 2013-06-20
US8110179B2 (en) 2012-02-07
US8475781B2 (en) 2013-07-02
US8609081B2 (en) 2013-12-17
TWI422379B (en) 2014-01-11
KR20050038039A (en) 2005-04-25
BR122012021252B8 (en) 2021-05-25
ES2377318T3 (en) 2012-03-26
US20130131013A1 (en) 2013-05-23
CN102516417B (en) 2014-12-10
US8404662B2 (en) 2013-03-26
AU2009251190B2 (en) 2012-08-09
KR101268258B1 (en) 2013-05-31
TW201221132A (en) 2012-06-01
KR20180004322A (en) 2018-01-10
BRPI0314042B8 (en) 2021-05-25
CY1112362T1 (en) 2015-12-09
EP1534340B1 (en) 2011-11-16
ES2417324T3 (en) 2013-08-07
JP2014167022A (en) 2014-09-11
US20120301424A1 (en) 2012-11-29
US7270808B2 (en) 2007-09-18
BR0314042A (en) 2005-07-05
US20120178711A1 (en) 2012-07-12
BRPI0314042B1 (en) 2020-02-11
EP2277551B1 (en) 2013-05-08
JP2012082220A (en) 2012-04-26
CA2497792C (en) 2014-08-05
US8580244B2 (en) 2013-11-12
US20130196945A1 (en) 2013-08-01
EP3332811A1 (en) 2018-06-13
US20140288023A1 (en) 2014-09-25
US8680202B2 (en) 2014-03-25
JP2006502301A (en) 2006-01-19
MX367615B (en) 2019-08-28
KR101857900B1 (en) 2018-05-14
TWI366464B (en) 2012-06-21
EP2402036A1 (en) 2012-01-04
HK1254600A1 (en) 2019-07-26
US20130190450A1 (en) 2013-07-25
US8580242B2 (en) 2013-11-12
EP2277551A2 (en) 2011-01-26
PT2277551E (en) 2013-08-22
EP2277551A3 (en) 2011-11-23
EP2402036B1 (en) 2018-02-14
US20120289480A1 (en) 2012-11-15
US20120283214A1 (en) 2012-11-08
PT1534340E (en) 2012-03-13
CA2497792A1 (en) 2004-03-18
KR20120104412A (en) 2012-09-20
JP5681646B2 (en) 2015-03-11
JP2011080089A (en) 2011-04-21
US8603454B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
HK1254600A1 (en) Cyclodextrin-based polymers for delivering covalently attached camptothecin
WO2006089007A3 (en) Cyclodextrin-based polymers containing photocleavable linkers for drug delivery
WO2008076333A3 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
Hong et al. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform
Lai Cyclodextrins in non-viral gene delivery
Zhang et al. Disulfide bond based polymeric drug carriers for cancer chemotherapy and relevant redox environments in mammals
WO2001028591A3 (en) Injection vehicle for polymer-based formulations
WO2004105782A3 (en) Drug delivery systems for tumor targeting ngr-molecules and uses thereof
ATE342054T1 (en) METHOD AND COMPOSITION FOR TREATING CANCER
WO2004093795A3 (en) Compositions for delivery of drug combinations
WO2007076371A3 (en) Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
Baraldi et al. Hybrid molecules between distamycin A and active moieties of antitumor agents
WO2005028516A3 (en) Albumin-binding derivatives of therapeutic peptides
WO2007004067A3 (en) Methods and compositions for the delivery of biologically active agents
UA103758C2 (en) Insulin-oligomer conjugates, formulations and uses thereof
England et al. Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers
WO2005058367A3 (en) Pegylated small molecules
SI1560854T1 (en) Taxanes covalently bound to hyaluronic acid or hyaluronic acid derivatives
Park et al. Water-soluble heparin–PTX conjugates for cancer targeting
WO2004004598A3 (en) Polymerized and modified rapamycins and their use in coating medical prostheses
WO2006073430A3 (en) Therapeutic delivery system comprising a high molecular weight peg-like compound
Cheng et al. The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials
Tai et al. A novel rapamycin-polymer conjugate based on a new poly (ethylene glycol) multiblock copolymer
Hegde et al. An update on design and pharmacology of dendritic poly (l-lysine)
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 167169

Country of ref document: IL

Ref document number: 2003278764

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/002444

Country of ref document: MX

Ref document number: 2005/01848

Country of ref document: ZA

Ref document number: 200501848

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2497792

Country of ref document: CA

Ref document number: 2004569982

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057003918

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003770286

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005110059

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057003918

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038248298

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003770286

Country of ref document: EP